Publications scientifiques

Acyclovir Lauriad^®: A muco-adhesive buccal tablet for the treatment of recurrent herpes labialis
« In clinical trials, a single application of acyclovir muco-adhesive buccal tablet resulted in high exposure of acyclovir to saliva and oral mucosa, and levels were sustained for 24 h. This is a major advantage over oral acyclovir as it requires frequent dosing due to its low bioavailability. »
Published in « Expert Review of Anti-Infective Therapy », January 2014

Efficacy and Safety of Aciclovir Mucoadhesive Buccal Tablet in Immunocompetent Patients With Labial Herpes (LIP Trial): A Double-Blind, Placebo-Controlled, Self-Initiated Trial
« A single application of ABT improves all endpoints of HL and might modify its clinical course in decreasing the incidence and delaying the onset of the next recurrence. »
Published in « Journal of Drugs in Dermatology (JDD) », July 2014

Recurrent herpes labialis in Adults : New tricks for an old dog
« In short, Acyclovir Buccal Tablet is the first antiviral drug that has demonstrated reduction in the number of fever blister outbreaks following an episodic treatment. »
Published in « Journal of Drugs in Dermatology (JDD) », March 2017

Pragmatic and profound benefits of Acyclovir Buccal adhesive tablets
« Results of pivotal trials indicate that usage, starting within one hour of prodrome ontset, can hasten episode resolution, reduce time to healing of primary lesion, reduce the number of future outbreaks, and increase the time between subsequent outbreaks. »
Published in « Journal of Drugs in Dermatology (JDD) », June 2016

Comparison of the Efficacy and Safety of Miconazole 50-mg Mucoadhesive BuccalTablets With Miconazole 500-mg Gel in theTreatment of Oropharyngeal Candidiasis
« The efficacy of MBT was achieved with a 10-fold lower miconazole dose than that of the topical gel (50 mg vs 500 mg) using a once-daily administration schedule instead of a 4-times-daily administration. »
Published in « ACS Journals », November 2007

Plasma, saliva and labial mucosa pharmacokinetics and pharmacodynamics of acyclovir Lauriad^® mucoadhesive buccal tablet in healthy volunteers
« The ABT delivery system provides earlier, higher and more sustained concentrations of acyclovir than acyclovir 200 mg oral tablet in saliva and mucosa. »
Published in « Journal of Clinical Pharmacology & Clinical Pharmacokinetics », March 7 2014

Mouth to Mouth
« Prolonging the residence time of drugs administered topically in the oral cavity is a major challenge. This has been overcome with the developement of mucoadhesive buccal tablets with sustained release properties. »
Published in ebr, July 2014